Honasa Consumer, the Gurugram-based parent company of Mamaearth, has acquired a 58% majority stake in Fluence Pharma through a secondary purchase at an enterprise value of Rs 135 Cr (approximately $16 million), as publicly reported on June 23, 2026. The deal is a strategic acquisition — not a venture funding round — with no external lead investor involved. The move signals Honasa’s formal entry into the fast-growing nutraceuticals and consumer health space.
Quick Highlights
- Enterprise Value: Rs 135 Cr (~$16M) for a 58% stake
- Honasa Founders: Varun Alagh and Ghazal Alagh
- Fluence Pharma Founders: Amit Bhusari and Dr. Rajendra Singh Rajput (founded 2012)
- Deal Type: Strategic acquisition — no external investors
- Headquarters: Honasa — Gurugram, India; Fluence Pharma — India
- Announcement Date: June 23, 2026
Funding Breakdown
Use of Funds
The acquisition is designed to integrate Fluence Pharma’s proprietary Customized Nutraceutical Therapy (CNT) platform and its network of over 3,000 dermatologists into Honasa’s existing brand strength and digital distribution infrastructure. The combined entity will power the launch of a dedicated B2C nutraceuticals vertical under the new subsidiary, Honasa Health Private Limited.
Funding Timeline
This transaction marks the first formal deal between the two companies. Honasa has acquired 58% of Fluence Pharma in the current tranche, with the remaining 42% stake to be acquired in two additional tranches over a five-to-seven-year period.
Expansion Plans
Honasa will establish Honasa Health Private Limited as a wholly-owned subsidiary to build out a standalone B2C nutraceuticals business. The phased acquisition structure — two tranches completing full ownership over five to seven years — suggests a measured integration approach, allowing Fluence Pharma’s clinical and professional networks to be absorbed systematically into Honasa’s consumer-facing ecosystem.
Significance
Fluence Pharma reported revenue of Rs 40 Cr in FY26 with an EBITDA margin exceeding 20%, giving Honasa a profitable and operationally mature platform to build on rather than starting from scratch. India’s nutraceuticals market is valued at over Rs 16,000 Cr, representing a meaningful adjacency to Honasa’s core beauty and personal care portfolio. This deal places Honasa alongside a broader consolidation wave in Indian beauty and wellness — a trend that has also seen major FMCG and beauty conglomerates pursue similar bolt-on acquisitions in the health and nutrition space. For Honasa specifically, adding a dermatologist-linked CNT platform differentiates its nutraceuticals play from generic supplement brands and lends it clinical credibility from day one.
These details have been verified against multiple publicly available reports as of June 23, 2026.
Stay up to date with the latest startup funding news on The Courtroom.
Disclaimer: This report is compiled from publicly available sources and is for informational purposes only; funding figures are as publicly reported and may be subject to change.
